Thinking of joining a study?

Register your interest

Become a volunteer?

NCT07041099 | RECRUITING | Sjögren

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Sponsor:

Cullinan Therapeutics Inc.

Brief Summary:

A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.

Condition or disease

Sjögren

Sjogren Disease

Sjogren's Syndrome

Intervention/treatment

CLN-978

Phase

PHASE1

Study Type : INTERVENTIONAL
Estimated Enrollment : 36 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren's Disease
Actual Study Start Date : 2025-10-01
Estimated Primary Completion Date : 2028-03-15
Estimated Study Completion Date : 2029-03-15

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion
  • * Diagnosis of SjD at least 24 weeks prior to Screening Visit and meet the 2016 EULAR / ACR Classification Criteria for SjD at Screening.
  • * Have active moderate to severe disease (i.e., ESSDAI ≥5) at Screening.
  • * Laboratory parameters including the following
    • * Absolute lymphocyte count (ALC) ≥0.5 × 10\^9/L
    • * Peripheral CD19+ B cell count ≥25 cells/µL
    • * Absolute neutrophil count (ANC) ≥1.0 × 10\^9/L
    • * Hemoglobin (Hgb) ≥8 g/dL
    • * Platelet count ≥75 × 10\^9/L
    • * Total bilirubin ≤1.5 × ULN, except patients with confirmed Gilbert's Syndrome
    • * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.0 × ULN
    • * Estimated glomerular filtration rate (eGFR) based on the CKD-EPI formula ≥30 mL/min/1.73 m2
    • Exclusion
    • * Concomitant rheumatological autoimmune disease
    • * Considered at high risk for thrombosis
    • * Rapidly progressive glomerulonephritis and/or urine protein/creatinine \>3 mg/mg (339 mg/mmol).
    • * Active, severe central nervous system manifestations of SjD.
    • * History of stroke, seizure, dementia, Parkinson's disease, coordination movement disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic disorder that the Investigator feels would put the patient at undue risk or confound study results.
    • * Evidence of hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), or cytomegalovirus (CMV) infection.
    • * Primary immunodeficiency or history of recurrent infections.
    • * History of splenectomy.
    • * Live or attenuated vaccine within 28 days prior to the Screening Visit or during the Screening Period.
    • * Active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, within 14 days prior to Day 1.
    • * Active or latent tuberculosis (TB)
    • A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

    Location Details

    NCT07041099

    Please Choose a site

    How to Participate

    Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

    Locations

    RECRUITING

    United States, Texas

    Cullinan Investigative Site

    Plano, Texas, United States, 75093

    RECRUITING

    United States, Utah

    Cullinan Investigative Site

    Salt Lake City, Utah, United States, 84107

    RECRUITING

    Germany,

    Cullinan Investigative Site

    Erlangen, Germany,